Synchron Raises $200M in Series D to Boost BCI Commercialization
Synchron announced it has secured $200 million in a Series D funding round to accelerate the commercialization of its brain-computer interface (BCI) system, Stentrode. Based in New York, the company will use the capital to fast-track pivotal trials and support the launch of Stentrode.
Funding and Development Plans
This latest financing increases Synchron’s total funding to $345 million. The company intends to expand its team by hiring engineers, neuroscientists, and operators to advance both current and next-generation BCIs. A new engineering hub in San Diego was also established to develop an advanced brain interface.
Cognitive AI Initiatives
Synchron plans to leverage its growing Cognitive AI division in New York to develop models that decode brain signals in real time, learning directly from brain data.
Investment Details
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
About Stentrode Technology
Stentrode is uniquely implanted via an endovascular approach through the jugular vein, placing the device on the surface of the brain's motor cortex. It captures motor intention signals directly from blood vessels inside the brain, making it the only BCI that taps into the vascular system to detect brain signals.
"Synchron says its BCI is the only one tapping into blood vessels to capture signals from the brain."
Author's summary: Synchron’s $200 million funding round will accelerate trials and next-gen brain-computer interfaces, uniquely leveraging vascular pathways for real-time neural signal decoding.